A Randomized, Double-blinded Pivotal Study of the Safety and Efficacy of a Novel Intraoral Photobiomodulation Device in Head and Neck Cancer Patients Undergoing Radiation Therapy With or Without Vhemotherapy

Oral mucositis (OM) is a significant adverse event (AE) that affects over 90% of head and neck cancer (HNC) patients undergoing radiation (RT) with chemotherapy (CT). OM is characterized by ulceration, erythema, and edema of the oral tissues and can result in interruptions in and/or early termination of cancer treatment, increased opioid usage, and decreased alimentation and quality of life. Pharmacological interventions for OM are limited; however supportive care treatment guidelines (MASCC, WALT) recommend photobiomodulation (PBM) therapy for the prevention/treatment of OM.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: 185 Source Type: research